Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Proprietary Name Review Letter - Novoeight

DEPARTMENT OF HEALTH & HUMAN SERVICES                                                     Public Health Service

                                                                                                                            Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448


Our Reference:  STN BL 125466/0
Novo Nordisk, Inc.
Attention: Robert B. Clark
P.O. Box 846
Plainsboro, NJ 08536
Dear Mr. Clark:
We have reviewed your submission dated October 15, 2012 to your biologics license application (BLA) for Antihemophilic Factor (Recombinant), Plasma/Albumin Free, requesting a proprietary name review.
In consultation with CBER’s Advertising and Promotional Labeling Branch (APLB) we conclude that under the Federal Food, Drug, and Cosmetic Act and applicable regulations, your proposed proprietary name, NOVOEIGHT, is acceptable at this time.
If you have any questions, please contact Leigh Pracht at (301) 827-6116.
Sincerely yours,
Basil Golding, MD
Division of Hematology
Office of Blood Research and Review
Center for Biologics
 Evaluation and Research

Page Last Updated: 11/15/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English